Hypertension

VIATORR Endoprosthesis receives FDA approval

Published in Medical Letter on the CDC and FDA, January 16th, 2005

W. L. Gore & Associates, Inc., has received U.S. Food and Drug Administration (FDA) approval to market the GORE VIATORR Endoprosthesis, an advanced-technology, implantable device to treat portal hypertension in both de novo and revision Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedures.

The VIATORR Endoprosthesis is also indicated for the treatment of tracheobronchial strictures.

The GORE VIATORR TIPS Endoprosthesis is a flexible, self-expanding, implantable endoprosthesis with a proprietary, reduced permeability expanded polytetrafluoroethylene (ePTFE) graft lining. Featuring improved radial compression strength over other commercial...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2005-01-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry